GCP
PRAX icon

GSA Capital Partners’s Praxis Precision Medicines PRAX Stock Holding History

GSA Capital Partners’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,740
Closed -$304K – 1999
2025
Q3 		$304K Sell
5,740
-6,268
-52% -$304K 0.03% 1189
2025
Q2 		$505K Sell
12,008
-969
-7% -$36.9K 0.04% 920
2025
Q1 		$491K Buy
12,977
+7,295
+128% +$456K 0.04% 812
2024
Q4 		$437K Buy
+5,682
New +$411K 0.03% 983
2023
Q4 		– Sell
-2,237
Closed -$57K – 1833
2023
Q3 		$57K Buy
2,237
+1,417
+173% +$26.8K ﹤0.01% 1413
2023
Q2 		$14K Buy
+820
New +$12.6K ﹤0.01% 1449
2022
Q1 		– Sell
-715
Closed -$211K – 1743
2021
Q4 		$211K Buy
+715
New +$210K 0.03% 1181

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

GSA Capital Partners's PRAX Position: Q4 2025 in Review

GSA Capital Partners sold out of Praxis Precision Medicines (PRAX) in Q4 2025, closing a stake of 5,740 shares — an estimated $304K sold.

GSA Capital Partners first reported a position in PRAX in Q4 2021 and held it in 7 quarters. The position peaked at $505K in Q2 2025. 250 funds tracked by Wall St. Rank hold PRAX as of Q4 2025.

  • GSA Capital Partners reported no remaining Praxis Precision Medicines position as of Q4 2025 after selling out during the quarter.
  • GSA Capital Partners sold 5,740 Praxis Precision Medicines shares in Q4 2025, an estimated $304K.
  • GSA Capital Partners first reported a position in Praxis Precision Medicines in Q4 2021 and held it in 7 quarters.
  • GSA Capital Partners's Praxis Precision Medicines position peaked at $505K in Q2 2025.
  • 250 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q4 2025.

Based on GSA Capital Partners's 13F filing for Q4 2025, filed 6 Feb 2026.